Dopaminergic neurons respond to iron-induced oxidative stress by modulating lipid acylation and deacylation cycles

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Campos, Sofía Sánchez ^a   Diez, Guadalupe Rodríguez ^a   Oresti, Gerardo Martín ^a   Salvador, Gabriela Alejandra ^a  

^a UNIVERSIDAD NACIONAL DEL SUR   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; COPPER; IRON; OLEIC ACID; PHOSPHOLIPID; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL;

ACYLATION; ANIMAL CELL; ARTICLE; CELL BODY ROUNDING; CELL COUNT; CELL DAMAGE; CELL LABELING; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASMIC RETRACTION; CYTOTOXICITY; DEACYLATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; INTRACELLULAR SIGNALING; IRON OVERLOAD; LIPID METABOLISM; LIPID PEROXIDATION; LIPID TRANSPORT; NERVE CELL LESION; NERVE CELL MEMBRANE STEADY POTENTIAL; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; ANIMAL; CELL LINE; CHEMISTRY; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; OXIDATION REDUCTION REACTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACYLATION; ANIMALS; ARACHIDONIC ACID; CELL LINE; COPPER; DOPAMINERGIC NEURONS; IRON; IRON OVERLOAD; LIPID METABOLISM; LIPID PEROXIDATION; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; OLEIC ACID; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; PHOSPHOLIPIDS; RATS; REACTIVE OXYGEN SPECIES; TRIGLYCERIDES;

EID: 84937060871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130726     Document Type: Article

References (46)

1. Barnham KJ, Bush AI (2008) Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol 12: 222-228. S1367-5931(08)00041-0 [pii];doi: 10.1016/j.cbpa.2008.02.019 PMID: 18342639
2. Dias V, Junn E, Mouradian MM (2013) The role of oxidative stress in Parkinson's disease. J Parkinsons Dis 3: 461-491. B5502M7312389W87 [pii];doi: 10.3233/JPD-130230 PMID: 24252804
3. Kell DB (2010) Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 84: 825-889. doi: 10.1007/s00204-010-0577-x PMID: 20967426
4. Raha AA, Vaishnav RA, Friedland RP, Bomford A, Raha-Chowdhury R (2013) The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer's disease. Acta Neuropathol Commun 1: 55. 2051-5960-1-55 [pii];doi: 10.1186/2051-5960-1-55 PMID: 24252754
5. Devos D, Moreau C, Dujardin K, Cabantchik I, Defebvre L, Bordet R (2013) New pharmacological options for treating advanced Parkinson's disease. Clin Ther 35: 1640-1652. S0149-2918(13)00891-6 [pii];doi: 10.1016/j.clinthera.2013.08.011 PMID: 24011636
6. Gal S, Fridkin M, Amit T, Zheng H, Youdim MB (2006) M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. J Neural Transm Suppl 447-456. PMID: 17017567
7. Zhu Y, Hoell P, Ahlemeyer B, Sure U, Bertalanffy H, Krieglstein J (2007) Implication of PTEN in production of reactive oxygen species and neuronal death in in vitro models of stroke and Parkinson's disease. Neurochem Int 50: 507-516. S0197-0186(06)00326-3 [pii];doi: 10.1016/j.neuint.2006.10.010 PMID: 17169462
8. Howitt J, Gysbers AM, Ayton S, Carew-Jones F, Putz U, Finkelstein DI, Halliday GM, Tan SS (2014) Increased Ndfip1 in the substantia nigra of parkinsonian brains is associated with elevated iron levels. PLoS One 9: e87119. doi: 10.1371/journal.pone.0087119;PONE-D-13-33740 [pii]. PMID: 24475238
9. Davies KM, Bohic S, Carmona A, Ortega R, Cottam V, Hare DJ, et al.(2014) Copper pathology in vulnerable brain regions in Parkinson's disease. Neurobiol Aging 35: 858-866. S0197-4580(13)00436-3 [pii];doi: 10.1016/j.neurobiolaging.2013.09.034 PMID: 24176624
10. Double KL (2012) Neuronal vulnerability in Parkinson's disease. Parkinsonism Relat Disord 18 Suppl 1: S52-S54. S1353-8020(11)70018-9 [pii];doi: 10.1016/S1353-8020(11)70018-9 PMID: 22166454
11. Farooqui AA (2009) Lipid mediators in the neural cell nucleus: their metabolism, signaling, and association with neurological disorders. Neuroscientist 15: 392-407. 15/4/392 [pii];doi: 10.1177/1073858409337035 PMID: 19666894
12. Farooqui AA, Horrocks LA (2006) Phospholipase A2-Generated Lipid Mediators in the Brain: The Good, the Bad, and the Ugly. The Neuroscientist 12: 245-260. PMID: 16684969
13. Perez-Chacon G, Astudillo AM, Balgoma D, Balboa MA, Balsinde J (2009) Control of free arachidonic acid levels by phospholipases A2 and lysophospholipid acyltransferases. Biochim Biophys Acta 1791: 1103-1113. S1388-1981(09)00193-0 [pii];doi: 10.1016/j.bbalip.2009.08.007 PMID: 19715771
14. Shindou H, Shimizu T (2009) Acyl-CoA:lysophospholipid acyltransferases. J Biol Chem 284: 1-5. R800046200 [pii];doi: 10.1074/jbc.R800046200 PMID: 18718904
15. Wilfling F, Haas JT, Walther TC, Farese RV Jr. (2014) Lipid droplet biogenesis. Curr Opin Cell Biol 29: 39-45. S0955-0674(14)00042-8 [pii];doi: 10.1016/j.ceb.2014.03.008 PMID: 24736091
16. Gui YX, Xu ZP, Wen L, Liu HM, Zhao JJ, Hu XY (2013) Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease. Parkinsonism Relat Disord 19: 21-26. S1353-8020(12)00307-0 [pii];doi: 10.1016/j.parkreldis.2012.07.016 PMID: 23182313
17. Lee YJ, Wang S, Slone SR, Yacoubian TA, Witt SN (2011) Defects in very long chain fatty acid synthesis enhance alpha-synuclein toxicity in a yeast model of Parkinson's disease. PLoS One 6: e15946. doi: 10.1371/journal.pone.0015946 PMID: 21264320
18. Ruiperez V, Darios F, Davletov B (2010) Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res 49: 420-428. S0163-7827(10)00029-9 [pii];doi: 10.1016/j.plipres.2010.05.004 PMID: 20580911
19. Uranga RM, Giusto NM, Salvador GA (2009) Iron-induced oxidative injury differentially regulates PI3K/Akt/GSK3beta pathway in synaptic endings from adult and aged rats. Toxicol Sci 111: 331-344. kfp152 [pii];doi: 10.1093/toxsci/kfp152 PMID: 19608791
20. Rodriguez DG, Sanchez CS, Giusto NM, Salvador GA (2013) Specific roles for Group V secretory PLA (2) in retinal iron-induced oxidative stress. Implications for age-related macular degeneration. Exp Eye Res 113: 172-181. S0014-4835(13)00138-3 [pii];doi: 10.1016/j.exer.2013.05.019 PMID: 23791636
21. Uranga RM, Katz S, Salvador GA (2013) Enhanced phosphatidylinositol 3-kinase (PI3K)/Akt signaling has pleiotropic targets in hippocampal neurons exposed to iron-induced oxidative stress. J Biol Chem 288: 19773-19784. M113.457622 [pii];doi: 10.1074/jbc.M113.457622 PMID: 23687303
22. Uranga RM, Mateos MV, Giusto NM, Salvador GA (2007) Activation of phosphoinositide-3 kinase/Akt pathway by FeSO4 in rat cerebral cortex synaptic endings. J Neurosci Res 85: 2924-2932. doi: 10.1002/jnr.21406 PMID: 17600839
23. Rouser G, Fkeischer S, Yamamoto A (1970) Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 5: 494-496. PMID: 5483450
24. BLIGH EG, DYER WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917. PMID: 13671378
25. Rodriguez DG, Uranga RM, Mateos MV, Giusto NM, Salvador GA (2012) Differential participation of phospholipase A2 isoforms during iron-induced retinal toxicity. Implications for age-related macular degeneration. Neurochem Int 61: 749-758. S0197-0186(12)00209-4 [pii];doi: 10.1016/j.neuint.2012.06.012 PMID: 22732705
26. Mateos MV, Uranga RM, Salvador GA, Giusto NM (2008) Activation of phosphatidylcholine signalling during oxidative stress in synaptic endings. Neurochem Int 53: 199-206. S0197-0186(08)00110-1 [pii]; doi: 10.1016/j.neuint.2008.07.005 PMID: 18692105
27. Mateos MV, Giusto NM, Salvador GA (2012) Distinctive roles of PLD signaling elicited by oxidative stress in synaptic endings from adult and aged rats. Biochim Biophys Acta 1823: 2136-2148. S0167-4889(12)00262-5 [pii];doi: 10.1016/j.bbamcr.2012.09.005 PMID: 23010583
28. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20: 6048-6054. 20/16/6048 [pii]. PMID: 10934254
29. Mounsey RB, Teismann P (2012) Chelators in the treatment of iron accumulation in Parkinson's disease. Int J Cell Biol 2012: 983245. doi: 10.1155/2012/983245 PMID: 22754573
30. Sian-Hulsmann J, Mandel S, Youdim MB, Riederer P (2011) The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 118: 939-957. doi: 10.1111/j.1471-4159.2010.07132.x PMID: 21138437
31. Dusek P, Jankovic J, Le W (2012) Iron dysregulation in movement disorders. Neurobiol Dis 46: 1-18. S0969-9961(12)00009-5 [pii];doi: 10.1016/j.nbd.2011.12.054 PMID: 22266337
32. Stayte S, Vissel B (2014) Advances in non-dopaminergic treatments for Parkinson's disease. Front Neurosci 8: 113. doi: 10.3389/fnins.2014.00113 PMID: 24904259
33. Glynn P (2013) Neuronal phospholipid deacylation is essential for axonal and synaptic integrity. Biochim Biophys Acta 1831: 633-641. S1388-1981(12)00158-8 [pii];doi: 10.1016/j.bbalip.2012.07.023 PMID: 22903185
34. Balboa MA, Balsinde J (2006) Oxidative stress and arachidonic acid mobilization. Biochim Biophys Acta 1761: 385-391. S1388-1981(06)00075-8 [pii];doi: 10.1016/j.bbalip.2006.03.014 PMID: 16651022
35. Bazan NG (2005) Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol 32: 89-103. MN:32:1:089 [pii];doi: 10.1385/MN:32:1:089 PMID: 16077186
36. Sun GY, Xu J, Jensen MD, Simonyi A (2004) Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res 45: 205-213. doi: 10.1194/jlr.R300016-JLR200; R300016-JLR200 [pii]. PMID: 14657205
37. Else PL, Kraffe E (2014) Docosahexaenoic and arachidonic acid peroxidation: It's a within molecule cascade. Biochim Biophys Acta 1848: 417-421. S0005-2736(14)00374-5 [pii];doi: 10.1016/j.bbamem.2014.10.039 PMID: 25450347
38. Khaselev N, Murphy RC (1999) Susceptibility of plasmenyl glycerophosphoethanolamine lipids containing arachidonate to oxidative degradation. Free Radic Biol Med 26: 275-284. S0891-5849(98)00211-1 [pii]. PMID: 9895217
39. Hulbert AJ (2003) Life, death and membrane bilayers. J Exp Biol 206: 2303-2311. PMID: 12796449
40. Ulmann L, Mimouni V, Roux S, Porsolt R, Poisson JP (2001) Brain and hippocampus fatty acid composition in phospholipid classes of aged-relative cognitive deficit rats. Prostaglandins Leukot Essent Fatty Acids 64: 189-195. S0952-3278(01)90260-1 [pii];doi: 10.1054/plef.2001.0260 PMID: 11334555
41. Shinzawa K, Sumi H, Ikawa M, Matsuoka Y, Okabe M, Sakoda S, et al. (2008) Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease. J Neurosci 28: 2212-2220. 28/9/2212 [pii];doi: 10.1523/JNEUROSCI.4354-07.2008 PMID: 18305254
42. Adibhatla RM, Hatcher JF, Dempsey RJ (2003) Phospholipase A2, hydroxyl radicals, and lipid peroxidation in transient cerebral ischemia. Antioxid Redox Signal 5: 647-654. doi: 10.1089/152308603770310329 PMID: 14580322
43. Fonteh AN, Chiang J, Cipolla M, Hale J, Diallo F, Chirino A, et al. (2013) Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease. J Lipid Res 54: 2884-2897. jlr.M037622 [pii];doi: 10.1194/jlr.M037622 PMID: 23868911
44. Wilson-Ashworth HA, Judd AM, Law RM, Freestone BD, Taylor S, Mizukawa MK, et al. (2004) Formation of transient non-protein calcium pores by lysophospholipids in S49 Lymphoma cells. J Membr Biol 200: 25-33. doi: 10.1007/s00232-004-0691-x PMID: 15386157
45. Friedman JS, Chang B, Krauth DS, Lopez I, Waseem NH, Hurd RE, et al., (2010) Loss of lysophosphatidylcholine acyltransferase 1 leads to photoreceptor degeneration in rd11 mice. Proc Natl Acad Sci U S A 107: 15523-15528. 1002897107 [pii];doi: 10.1073/pnas.1002897107 PMID: 20713727
46. He Q, Wang M, Petucci C, Gardell SJ, Han X (2013) Rotenone induces reductive stress and triacylglycerol deposition in C2C12 cells. Int J Biochem Cell Biol 45: 2749-2755. S1357-2725(13)00300-2 [pii]; doi: 10.1016/j.biocel.2013.09.011 PMID: 24104397